A pharmaceutical representative presents a promotional brochure and a summary of the methodology for a recent clinical trial evaluating a novel lipid-lowering medication. As the evaluating physician, you must critically appraise the claims and study design. Match each excerpt from the promotional material or trial methodology with the biostatistical concept or potential bias it best exemplifies.
- Efficacy was calculated exclusively using data from subjects who completed the trial and took at least of their prescribed medication doses.Per-protocol analysis
- The brochure claims a reduction in myocardial infarction risk, highlighting the drop from a incidence in the placebo group to a incidence in the treatment group.Relative risk reduction
- The data and safety monitoring board halted the study at months during an interim analysis due to significant cardiovascular benefit, despite a planned -month duration.Early stopping bias
- Treating physicians were unblinded to patient allocation and provided more frequent cardiovascular monitoring and lifestyle counseling to the treatment group.Performance bias
Cevap
The correct matches map the trial's methodology and promotional claims to their respective epidemiological concepts: evaluating adherent patients only represents a per-protocol analysis, highlighting the proportional drop represents relative risk reduction, halting the trial early introduces early stopping bias, and differential follow-up introduces performance bias.
Each excerpt from the clinical trial methodology and drug advertisement maps to a specific biostatistical principle or bias that physicians must recognize when appraising medical literature. Understanding the differences between per-protocol and intention-to-treat analysis, relative versus absolute risk reduction, and forms of bias is critical for accurate evaluation.
Adım Adım Çözüm
Anahtar Kavram
Medical Literature and Drug Advertisement Interpretation